西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

薛梅萍; 郑茹萍; 林惠娥; 甘惠贞; 薛梅萍; 郑茹萍; 林惠娥; 甘惠贞

doi:10.3969/j.issn.1006-0111.2018.05.020

[1]

VANTYGHEM MC,PRESS M. Management strategies for brittle diabetes[J]. Ann Endocrinol(Paris),2006,67(4):287-296.

[2]

AMETOV AS,KULIDZHANIAN NK. Diabetes mellitus is an independent risk factor for cardiovascular disease[J]. Ter Arkh,2012,84:91-94.

[3]

KIM D,WANG L,BECONI M,et al. (2R)-4-oxo-4-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine:a potent,orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2005,48(6):141-151.

[4]

DRUKER DJ, NAUCK MA. GLP-1R agonists(incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes[J]. Lancet, 2006, 368(3):1696-1705.

[5]

DRUCKER DJ. Enhancing incretin action for the treatment of type 2 diabetes[J]. Diabetes Care,2003,26(10):2929-2940.

[6]

LIU XM. Special complication of diabetes[M]//LIU Xinmin. Practical endocrinology. 2nd ed. Beijing:People's Military Medical Publishing House, 1997:356-358.

[7]

郭慧,刘良专,刘江华. 降脂通络软胶囊联合瑞舒伐他汀对2型糖尿病合并高血脂症患者效果观察[J]. 重庆医学,2015,44(24):3348-3349.

[8]

HOLST JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide 1[J]. Diabetes Metab Res Rev,2002,18(6):430-441.

[9]

徐晓菲,吴玉波,吴禹蒙. 西格列汀对2型糖尿病患者血脂水平影响的系统评价[J]. 中国药房,2015,26(6):784-787.

[10]

罗娜,朱妍,张真稳,等. 西格列汀联合胰岛素治疗脆性糖尿病的临床观察[J]. 中南大学学报(医学版),2015,40(10):1089-1095.